Toumaz forms joint venture to commercialise its Sensium Digital Plaster
The company’s Sensium Digital Plaster has also received 510(k) approval from the Food and Drug Administration (‘FDA’) in the US. The Sensium Digital Plaster is an, ultra-small, ultra-low power wireless body-worn monitor that continuously and unobtrusively acquires high-quality vital signs data, including temperature, heart rate and respiration rate. The current Sensium Digital Plaster is targeted for use in hospital general ward environments. It also has the potential to be extended into telecare, chronic disease monitoring, community care settings and the home, where continuous or extended monitoring of patients is important.
Commenting on today’s announcements, Professor Chris Toumazou, Toumaz Limited Chief Executive, said: "We are very excited to be working closely with Dr. Patrick Soon-Shiong. We share his vision of building a better healthcare system by enabling remote patient monitoring. Dr. Patrick Soon-Shiong and his team bring considerable expertise in the development and distribution of medical devices and technology in the US. The extent of Dr. Patrick Soon-Shiong’s involvement in this venture illustrates the potential of the wireless healthcare market and our compelling proposition.”
Under the terms of the new partnership, California Capital Equity will provide up to $25M funding to the company over the next two years and will own 80% of the equity. The remaining 20% will be held by Toumaz Limited. Toumaz Limited will also receive both product and royalty revenues from the joint venture as it commercialises the Sensium Digital Plaster.
Visit Toumaz at www.toumaz.com
Related news:
Toumaz partners to commercialize RF chip for medical apps
RF group Toumaz joins health alliance standards body
Toumaz readies RF chip for medical monitoring
If you enjoyed this article, you will like the following ones: don't miss them by subscribing to :
